|Bid||0.00 x 1400|
|Ask||0.00 x 900|
|Day's range||82.92 - 86.55|
|52-week range||50.50 - 100.00|
|Beta (5Y monthly)||1.45|
|PE ratio (TTM)||N/A|
|Earnings date||07 Nov 2022 - 11 Nov 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||102.50|
Inari Medical's (NARI) second-quarter results benefit from significant progress made across all its growth drivers.
Joining me on today's call are Bill Hoffman, president and chief executive officer; Drew Hykes, chief operating officer; and Mitch Hill, chief financial officer. This call will include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
Inari Medical, Inc. (NARI) delivered earnings and revenue surprises of 17.39% and 5.34%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?